BRIEF published on 10/06/2026 at 22:10, 24 days 15 hours ago Inventiva reveals progress at the AASLD The Liver Meeting 2026 Inventiva Lanifibranor MASH Treatment AASLD 2026 PPAR Activation
BRIEF published on 10/06/2026 at 22:10, 24 days 15 hours ago Inventiva to Present Abstracts at 2026 Liver Meeting Inventiva MASH Lanifibranor PPAR Liver Meeting® 2026
PRESS RELEASE published on 10/06/2026 at 22:05, 24 days 15 hours ago Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026 Inventiva to present scientific abstracts on lanifibranor at AASLD The Liver Meeting® 2026, focusing on PPAR isoforms and epigenetic changes in MASH pathogenesis Inventiva MASH Lanifibranor AASLD PPAR Isoforms
BRIEF published on 09/08/2026 at 22:05, 1 month 22 days ago Inventiva to Showcase Lanifibranor Data at Paris MASH 2026 Clinical Data Inventiva MASH Lanifibranor PPAR Agonist
BRIEF published on 09/08/2026 at 22:05, 1 month 22 days ago Inventiva presents its advancements at the Paris MASH 2026 Congress Inventiva MASH Lanifibranor Clinical Phase PPAR
PRESS RELEASE published on 09/08/2026 at 22:00, 1 month 22 days ago Inventiva to Present Multiple Abstracts at Paris MASH 2026 Inventiva to present Phase 1 and Phase 2 clinical data on lanifibranor at Paris MASH 2026, showing improvements in metabolic and cardiovascular factors in MASH patients. Lanifibranor's pan-PPAR pharmacology highlighted Clinical Data Inventiva Lanifibranor Metabolic Dysfunction Paris MASH 2026
BRIEF published on 09/02/2026 at 22:10, 1 month 28 days ago Inventiva Completes Final Visit of the NATiV3 Lanifibranor Study Clinical Study Phase 3 Inventiva MASH Lanifibranor
BRIEF published on 09/02/2026 at 22:10, 1 month 28 days ago Inventiva Completes Key Milestone in MASH Clinical Trial Biopharmaceutical Inventiva Lanifibranor MASH Treatment NATiV3 Trial
PRESS RELEASE published on 09/02/2026 at 22:05, 1 month 28 days ago Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH Inventiva completes last patient visit in Phase 3 trial for lanifibranor in MASH treatment, with topline results expected in Q4 2026. Financial results update scheduled for H1 2026 Phase 3 Trial Inventiva Lanifibranor MASH Treatment Financial Results Update
BRIEF published on 08/31/2026 at 22:10, 1 month 30 days ago Chris Benecchi appointed COO by Inventiva Biopharmaceutical Inventiva MASH Lanifibranor Chris Benecchi
Published on 10/30/2026 at 23:35, 14 hours 27 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 14 hours 32 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 17 hours 15 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 19 hours 2 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 22 hours 32 minutes ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 15 hours 13 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 19 hours 24 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 18:35, 19 hours 27 minutes ago EQS-Adhoc: hep global GmbH expects to conclude refinancing negotiations only in fiscal year 2027
Published on 10/30/2026 at 23:00, 15 hours 2 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 20 hours 2 minutes ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 1 day 2 hours ago Capital increase through exercise of subscription rights
